134978-96-4

Basic information

• Product Name: {2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-acetic acid hydrochloride
• Synonyms: {2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-acetic acid hydrochloride
• CAS NO: 134978-96-4
• Molecular Weight: 243.688
• Mol File: 134978-96-4.mol

Chemical Properties

• CAS DataBase Reference: {2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-acetic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: {2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-acetic acid hydrochloride(134978-96-4)
• EPA Substance Registry System: {2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy}-acetic acid hydrochloride(134978-96-4)

Safety Data

• Hazardous Substances Data: 134978-96-4(Hazardous Substances Data)

Upstream product

• 86520-52-7 2-[2-(2-azidoethoxy)ethoxy]ethanol 
• 6338-55-2 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol 

Downstream Products

• 139338-72-0 (2-{2-[2-((9H-fluoren-9-ylmethoxycarbonyl)amino)-ethoxy]-ethoxy}-ethoxy)-acetic acid 

Relevant articles and documents

Multiple arms polymerization target anticancer conjugate

Disclosed is a multi-arm targeting drug conjugate modified by a water-soluble polymer; the drug conjugate has the structural formula of (III). In formula (III), R is an organic core, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is a camptothecin-based drug, and q is any integer between 3 and 8. The drug conjugate may improve the poor water solubility, high toxicity and low bioavailability of camptothecin-based drugs.

Targeting multi-arm conjugate (by machine translation)

The present invention discloses a multi-arm, by the water-soluble polymer modified folic acid receptor targeted drug conjugates and salts thereof. The drug conjugate has the following structural formula: The invention is a multi-arm polymer modified targeting anticancer conjugate, wherein the water-soluble polymer may be modified to enhance the water solubility of the conjugate, thereby increasing the drug loading. In the invention of targeting molecules for folic acid, folic acid as a targeting molecule, folic acid receptor expressing abundant active targeting of tumor cells, play a better anti-tumor efficacy, increase target, and thus make the concentration of the conjugate in the targeted tissue more high. (by machine translation)

Zinc(II)cyclen-peptide conjugates interacting with the weak effector binding state of Ras

Zinc(II)cyclen-peptide hybrid compounds and bis-zinc(II)cyclen complexes are prepared as potential binders of the guanine nucleotide binding protein Ras, an important molecular switch in cellular signal transduction. The design of the compounds is based on the previous observation that zinc(II)cyclen complexes could serve as lead compounds for inhibitors of Ras-effector interaction and thus be able to interrupt Ras induced signal transduction. Zinc(II)cyclen selectively stabilizes conformational state 1 of active Ras, a conformational state with drastically decreased affinity to effector proteins like Raf-kinase. To achieve higher binding affinities of such Ras-Raf interaction inhibitors, zinc(II)cyclen conjugates with short peptides, derived from the sequence of the Ras-activator SOS, were prepared by solid phase synthesis protocols. Dinuclear bis-zinc(II)cyclen complexes were obtained from alkyne-azide cycloaddition reactions. NMR investigations of the prepared compounds revealed that the peptide conjugates do not lead to an increase in Ras binding affinity of the metal complex-peptide conjugates. The dinuclear zinc complexes lead to an immediate precipitation of the protein prohibiting spectroscopic investigations of their binding.